# DY001: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery

> **NCT00596583** · PHASE3 · COMPLETED · sponsor: **Aqumen Biopharmaceuticals, N.A.** · enrollment: 300 (estimated)

## Conditions studied

- Mature Cataracts

## Interventions

- **DRUG:** DYME
- **DRUG:** DYME

## Key facts

- **NCT ID:** NCT00596583
- **Lead sponsor:** Aqumen Biopharmaceuticals, N.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2009-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00596583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00596583, "DY001: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00596583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*